Loading
A phase 1/2 trial of fludarabine, aldesleukin (high-dose il-2) and pembrolizumab in triple-negative breast cancer, run by Essen Biotech, now recruiting.
TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer is a phase 1/2, interventional study registered as NCT06532812 by Essen Biotech, with a registry enrolment figure of 85 participants, started 2024-08-22 and due to reach its primary completion in 2025-12-10. Interventions recorded: Tumor Infiltrating Lymphocytes (TIL); Cyclophosphamid; Fludarabine; Interleukin-2; Pembrolizumab. Conditions listed: Breast Cancer; Breast Carcinoma; Breast Cancer Metastatic; Breast Cancer Triple Negative. Sites: China. No results are recorded here; the registry entry is the source.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Pembrolizumab, Immune checkpoint inhibitors and the tag tnbc-deep-dive.
Shares Aldesleukin (high-dose IL-2), Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Pembrolizumab, Immune checkpoint inhibitors and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Pembrolizumab, Immune checkpoint inhibitors and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Pembrolizumab, Immune checkpoint inhibitors and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Pembrolizumab, Immune checkpoint inhibitors and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Immune checkpoint inhibitors and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Immune checkpoint inhibitors and the tag tnbc-deep-dive.